Aurinia Pharmaceuticals Inc (AUPH)

[Zeppo]

Aurinia re-traced over 50% of its original gain while the general markets were rising. So when the general markets got clobbered, Aurinia fell just a little over 10%. Can it go to $2? Sure. It's a stock. Current prospects, however, should put a floor underneath this stock at close to current levels. What could drop it farther? Another general market devaluation could do it. The biggest culprits, however, would be untimely reporting delays and/or a reduction in efficacy numbers from Phase III test results. We know to not expect any answers for several more months. So the waiting game continues, and we have to realize that, at times, the attitude of the general market will have an affect on Aurinia....psychological if nothing else.